FRIDAY, March 18 (HealthDay News) -- Patients with type 2 diabetes who take rosiglitazone are at greater risk of congestive heart failure, myocardial infarction (MI), and death, compared to those who take pioglitazone, according to a meta-analysis published online March 17 in BMJ.
Yoon Kong Loke, M.D., of the University of East Anglia in Norwich, U.K., and colleagues conducted a meta-analysis of 16 observational studies comparing the risk of cardiovascular outcomes for rosiglitazone and pioglitazone in patients with type 2 diabetes. The risk of MI, congestive heart failure, and mortality was assessed in 810,000 patients.
The researchers found that, compared with pioglitazone, use of rosiglitazone was linked with significantly increased odds of MI (odds ratio [OR], 1.16), congestive heart failure (OR, 1.22), and mortality (OR, 1.14). Numbers needed to treat to harm suggested that, among certain risk groups, there could be 170 excess MIs, 649 excess heart failure cases, and 431 excess deaths for every 100,000 patients who take rosiglitazone instead of pioglitazone.
"Clinicians, patients, and regulatory authorities should carefully consider these results in the context of the available information on the thiazolidinediones' benefits on glycemic control and harm relating to different outcomes," the authors write.